Table 1

Consortia that address various stages of the value chain.

Collaboration nameManaging entityGoals and links to information
Biomanufacturing Research Program (BIOman)MIT Center for Biomedical InnovationManufacturing and quality control of biopharmaceuticals; cbi.mit.edu/research-overview/bioman
Biomarkers ConsortiumFNIHBiomarker identification and qualification; www.biomarkersconsortium.org
Cancer CommonsSelf (nonprofit)Targeted treatments for patients with cancer; www.cancercommons.org
Clinical Data Interchange Standards Consortium (CDISC)Self (nonprofit)Data standards and health care information; www.cdisc.org
Center for Medical Technology Policy (CMTP)Self (nonprofit)Clinical research standards, infrastructure, and coverage/reimbursement policy; www.cmtpnet.org
Clinical Trials Transformation Initiative (CTTI)DukeImprove clinical trial quality and efficiency; www.ctti-clinicaltrials.org
Coalition Against Major Disease (CAMD)Critical Path InstituteTechnologies and tools in drug development for neurodegenerative diseases; www.c-path.org/camd.cfm
International Serious Adverse Event Consortium (iSAEC)Critical Path InstituteIdentify biomarkers that predict the risk of drug-related serious adverse events; www.saeconsortium.org
NEW Drug Development ParaDIGmS (NEWDIGS)MIT Center for Biomedical InnovationTransform global innovation system to more sustainably and reliably deliver new, better, affordable therapeutics to the right patients faster; cbi.mit.edu/research-overview/newdigs
PROTECTInnovative Medicines InitiativeTools and methods for safety monitoring; www.imi.europa.eu/content/protect
SAFE-TInnovative Medicines InitiativeIdentification of sensitive and predictive biomarkers of liver, kidney, and vascular system damages for use in clinical drug development; www.imi-safe-t.eu
Sage BionetworksSelf (nonprofit)Open-source molecular data gathering and analysis on human disease; http://sagebase.org